Company news

Neurocrine Biosciences, Inc. news in 2019

Neurocrine Biosciences, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

December 1, 2019

Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

November 3, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

October 13, 2019

Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

October 3, 2019

Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

September 29, 2019

Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

September 16, 2019

Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

September 10, 2019

Neurocrine Biosciences Reports Second Quarter 2019 Financial Results

July 28, 2019

Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease

July 9, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results

July 7, 2019

Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference

May 29, 2019

Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting

May 4, 2019

Neurocrine Biosciences Reports First Quarter 2019 Financial Results

April 28, 2019

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results

April 7, 2019

Decks in 2019